Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2024-02-14 Capital/Financing Update
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 14, 2024, reporting the entry into a material definitive agreement, specifically an At The Market Offering Agreement for the sale of common stock. The content focuses on the details of the financing arrangement, including commission rates, terms, and related legal opinions. There are no financial statements or comprehensive financial performance data included. The primary subject is an update on the company's capital raising activity through an ATM offering. According to the filing definitions, this fits best under Capital/Financing Update (CAP). The document length is 5769 characters, which is sufficient to provide substantive detail about the financing agreement rather than a brief announcement. Therefore, the classification is CAP with high confidence.
2024-02-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 24, 2024, reporting an event related to the publication of an international patent application by the World Intellectual Property Organization. The content is an announcement of a specific event (patent publication) and includes a press release as an exhibit. There are no financial statements, detailed financial data, or management discussion of financial results. The document is not a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, audit report, or governance information. It is a regulatory filing reporting a material event outside the scope of other specific categories. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2024-01-30 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-26 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-26 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-26 English
Regulatory Filings 2024
Regulatory Filings
2024-01-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.